Disclosures for "Polyneuropathy Symptoms Precede Diagnosis of Cardiomyopathy Among Individuals with Transthyretin Amyloidosis"
-
Dr. Halabi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca. Dr. Halabi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ionis. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Halabi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for PeerVoice. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas/Pfizer. Dr. Halabi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ADVI. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Intellia Therapeutics. The institution of Dr. Halabi has received research support from Pharnext. The institution of Dr. Halabi has received research support from AstraZeneca.
-
Author has nothing to disclose
-
Dr. Papas has received personal compensation for serving as an employee of AstraZeneca. Dr. Papas has stock in AstraZeneca.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
John Venditto has received personal compensation for serving as an employee of AstraZeneca . John Venditto has stock in AstraZeneca .
-
Author has nothing to disclose
-
Dr. Li has received personal compensation for serving as an employee of NextGen Jane. Dr. Li has received intellectual property interests from a discovery or technology relating to health care.
-
The institution of Dr. Young has received research support from NIH. The institution of Dr. Young has received research support from Open Philanthropy. The institution of Dr. Young has received research support from Siemens Healthineers. Dr. Young has received intellectual property interests from a discovery or technology relating to health care. Dr. Young has received personal compensation in the range of $500-$4,999 for serving as a Invited Speaker with Max Planck Institute.
-
Dr. Nair has received personal compensation for serving as an employee of Clarivate. Dr. Nair has stock in Clarivate.
-
Author has nothing to disclose